Linoleic acid

Generic Name: Linoleic acid

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₂O_₂

CAS Number: 60-33-3

Unique Ingredient Identifier: 9KJL21T0QJ

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

Acne
Dermatitis
Dry Skin

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults	2025/01/22	NCT06786520	Phase 1	Active, not recruiting	ViiV Healthcare
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)	2024/12/19	NCT06741397	Phase 2	Active, not recruiting	ViiV Healthcare
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1	2024/11/19	NCT06694805	Phase 3	Recruiting	ViiV Healthcare
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy	2024/03/28	NCT06336434	Phase 1	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)	2023/11/18	NCT06134362	Phase 3	Recruiting	ViiV Healthcare
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants	2021/11/09	NCT05112939	Phase 1	Completed	Janssen Research & Development, LLC
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females	2021/04/01	NCT04824131	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males	2020/12/31	NCT04692077	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)
A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries	2020/05/22	NCT04399551	Phase 3	Completed	ViiV Healthcare
Truncal Ultrasound Guided Regional Anesthesia for Implantation and Revision of Automatic Implantable Cardioverter Defibrillators (AICDs) and Pacemakers in Pediatric Patients	2019/12/03	NCT04184349	Phase 4	Completed	The University of Texas Health Science Center, Houston

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
NUPRIMOL CAP	nu-life nutrition ltd.	02010666	Capsule - Oral	340 MG	9/15/1997
EVENING PRIMROSE OIL + VIT E CAP	bioforce canada inc.	01983512	Capsule - Oral	375 MG	12/31/1993
BORAGE OIL CAPSULES	general nutrition canada inc.	02183226	Capsule - Oral	375 MG	10/15/2001
BLACK CURRANT SEED OIL CAP	pure life international prods inc.	02010070	Capsule - Oral	78 MG	12/31/1993
BORAGE OIL CAPSULES	bioforce canada inc.	01986333	Capsule - Oral	220 MG	12/31/1994
FLAXSEED OIL CAPSULES	general nutrition canada inc.	02185792	Capsule - Oral	144 MG	5/27/1998
EVENING PRIMROSE OIL 500MG CAPSULE	swiss herbal remedies ltd.	02122731	Capsule - Oral	345 MG	12/31/1985
GLA 130 PRIMROSE OIL	seroyal international inc.	02148137	Capsule - Oral	900 MG / CAP	1/31/1996
HUILE D'ONAGRE VITAMIN E	le naturiste j.m.b. inc.	00658332	Capsule - Oral	72 %	12/31/1987
EVENING PRIMROSE OIL CAP	pure life international prods inc.	01946846	Capsule - Oral	350 MG	12/31/1992

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.